Open for Enrollment Soon
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.
ALXN2023 - CONCORD (Antibody-Mediated Rejection after Kidney Transplant) - Clinical Trial
Email for Information
kitza.williams@duke.edu
What is the Purpose of this Study?
We are doing this study to find out if an experimental drug called ALXN2030 (the study drug) is a safe and effective option for people diagnosed with antibody-mediated rejection (AMR) of a transplanted kidney.
What is the Condition Being Studied?
Antibody-Mediated Rejection (AMR) of a Kidney After Transplant
Who Can Participate in the Study?
Adults ages 18-75 who:
- Are diagnosed with active or chronic active AMR
- Are vaccinated against meningococcal infection, pneumonia, and influenza
For more information, contact the study team at hanajoy.porter@duke.edu.
Age Group
Adults
What is Involved?
If you choose to join this study, you will get a random assignment to either:
- Get the study drug; OR
- Get a placebo (inactive substance with no drug in it)
The study drug or placebo is given as an intravenous (IV) infusion every 3 months. Participation in the study will last for about 3 years.
Study Details
Full Title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients with Antibody-Mediated Rejection after Kidney Transplantation
Principal Investigator
Stuart J. Knechtle, MD
Kidney/Pancreas Transplant Surgeon
Protocol Number
IRB:
PRO00117477
NCT:
NCT06744647
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment Soon
More Information
Email kitza.williams@duke.edu